AZTA
Azenta, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-18 | Cornog William L |
Director |
Buy↑
Filing footnotes — Common (Indirect)
Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $16.19 to $16.52. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. Reflects shares held in trusts beneficially owned by the reporting person, of which the reporting person, his spouse and children are beneficiaries, and as to which the reporting person is the trustee and has investment and voting power. |
Common
(I)
|
10,000 |
| 2026-05-15 | Starr Ephraim |
SVP, Gen Counsel & Secretary |
Tax↓
Filing footnotes — Common (Direct)
The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on May 15, 2026 of 12,593 restricted stock units held by the reporting person. |
Common
|
3,621 |
| 2026-04-28 | MARTIN WILLIAM E. III |
Chief Executive Officer |
Award↑
Filing footnotes — Common (Direct)
Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. The units will vest over three years, 33% on Apriil 18, 2027, 33% on Apriil 18, 2028, and 33% on Apriil 18, 2029. |
Common
|
17,790 |
| 2026-04-06 | MARTIN WILLIAM E. III |
Chief Executive Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-02-06 | Nova Tina Susan |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
5,663 |
| 2026-02-05 | Davis Robyn C |
Director |
Award↑
Filing footnotes — Restricted Stock Unit (Direct)
Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. Grant of Restricted Stock Units under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the units. |
Restricted Stock Unit
|
5,663 |
| 2026-02-05 | Madaus Martin D |
Director |
Award↑
Filing footnotes — Restricted Stock Unit (Direct)
Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. Grant of Restricted Stock Units under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the units. |
Restricted Stock Unit
|
5,663 |
| 2026-02-05 | McLaughlin Erica |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
5,663 |
| 2026-02-05 | Doshi Dipal |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
5,663 |
| 2026-02-05 | Koffey Quentin |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Annual grant of unrestricted shares under the Issuer's 2020 Equity Incentive Plan in connection with the Reporting Person's service on the Issuer's Board of Directors (the "Board"). The number of shares was determined based on an annual grant amount of $215,000 and a price per share of $37.97 based on the average daily closing price for the 20 trading-day period immediately preceding and including February 5, 2026. No amount was paid upon grant of the shares. |
Common Stock
|
5,663 |
| 2026-02-05 | Casal Frank |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
7,243 |
| 2025-11-24 | Marotta John |
Director, President and CEO |
Award↑
Filing footnotes — Common (Direct)
This amendment to Form 4 is being filed to correct the number of restricted stock units ("RSUs") previously reported. The original Form 4 filed on November 25, 2025 incorrectly stated that 122,269 RSUs were acquired. The correct number is 118,194 RSUs. As a result of this correction, the total number of securities beneficially owned following the reported transaction has also been revised to 213,193.78. All other information in the original Form 4 remains unchanged. |
Common
|
118,194 |
| 2025-11-24 | Zhou Ginger |
SVP and GM, Multiomics |
Award↑
Filing footnotes — Common (Direct)
Represents the grant of restricted stock units ("RSUs"). No amount was paid upon grant of the RSUs. The number of RSUs granted was determined by dividing the target award value by the average closing price of the Company's common stock over the 20 trading days ending on the date of grant. The RSUs are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 24, 2026. |
Common
|
13,042 |
| 2025-11-24 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Represents the grant of restricted stock units ("RSUs"). No amount was paid upon grant of the RSUs. The number of RSUs granted was determined by dividing the target award value by the average closing price of the Company's common stock over the 20 trading days ending on the date of grant. The RSUs are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 24, 2026. |
Common
|
36,681 |
| 2025-11-24 | Pirogova Olga |
SVP and CHRO |
Award↑
Filing footnotes — Common (Direct)
Represents the grant of restricted stock units ("RSUs"). No amount was paid upon grant of the RSUs. The number of RSUs granted was determined by dividing the target award value by the average closing price of the Company's common stock over the 20 trading days ending on the date of grant. The RSUs are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 24, 2026. |
Common
|
16,303 |
| 2025-11-24 | Starr Ephraim |
SVP, Gen Counsel & Secretary |
Award↑
Filing footnotes — Common (Direct)
Represents the grant of restricted stock units ("RSUs"). No amount was paid upon grant of the RSUs. The number of RSUs granted was determined by dividing the target award value by the average closing price of the Company's common stock over the 20 trading days ending on the date of grant. The RSUs are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 24, 2026. |
Common
|
34,235 |
| 2025-11-14 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Tax↓
Filing footnotes — Common (Direct)
The withholding of shares from the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2025 of 10,566 restricted stock units held by the reporting person. |
Common
|
3,039 |
| 2025-11-14 | Pirogova Olga |
SVP and CHRO |
Tax↓
Filing footnotes — Common (Direct)
The withholding of shares from the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2025 of 4,529 restricted stock units held by the reporting person. |
Common
|
1,553 |
| 2025-11-14 | Marotta John |
Director, President and CEO |
Tax↓
Filing footnotes — Common (Direct)
The withholding of shares from the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2025 of 27,872 restricted stock units held by the reporting person. |
Common
|
10,980 |
| 2025-11-14 | Zhou Ginger |
SVP and GM, Multiomics |
Tax↓
Filing footnotes — Common (Direct)
The withholding of shares from the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2025 of 4,582 restricted stock units held by the reporting person. |
Common
|
1,118 |
| 2025-09-10 | Marotta John |
Director, President and CEO |
Sell↓
Filing footnotes — Common (Direct)
The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on September 9, 2025 of 1,091 restricted stock units held by the reporting person. |
Common
|
316 |
| 2025-08-12 | Pirogova Olga |
SVP and CHRO |
Sell↓
Filing footnotes — Common (Direct)
This amendment is being filed to include the Power of Attorney authorizing the undersigned to sign and file Forms 3, 4, and 5 on behalf of the reporting person, which was inadvertently not included with the original Form 4 filed on August 13, 2025. This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on August 13, 2025. The transaction was inadvertently reported using transaction code "D" instead of the correct code "S." |
Common
|
1,085 |
| 2025-08-12 | Zhou Ginger |
SVP and GM, Multiomics |
Sell↓
Filing footnotes — Common (Direct)
This amendment is being filed to include the Power of Attorney authorizing the undersigned to sign and file Forms 3, 4, and 5 on behalf of the reporting person, which was inadvertently not included with the original Form 4 filed on August 13, 2025. This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on August 13, 2025. The transaction was inadvertently reported using transaction code "D" instead of the correct code "S." |
Common
|
1,085 |
| 2025-08-11 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Other↑
|
No Securities Owned
|
0 |
| 2025-06-02 | Marotta John |
Director, President and CEO |
Buy↑
Filing footnotes — Common (Direct)
This amendment is being filed to include the Power of Attorney authorizing the undersigned to sign and file Forms 3, 4, and 5 on behalf of the reporting person, which was inadvertently not included with the original Form 4 filed on June 4, 2025. This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on June 4, 2025. The transaction was inadvertently reported using transaction code "A" instead of the correct code "P." |
Common
|
1,000 |
| 2025-05-30 | Malus Alan J |
Director |
Buy↑
Filing footnotes — Common (Direct)
This amendment is being filed to include the Power of Attorney authorizing the undersigned to sign and file Forms 3, 4, and 5 on behalf of the reporting person, which was inadvertently not included with the original Form 4 filed on June 3, 2025. This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on June 3, 2025. The transaction was inadvertently reported using transaction code "A" instead of the correct code "P." |
Common
|
12,000 |
| 2025-05-20 | Cornog William L |
Director |
Buy↑
Filing footnotes — Common (Direct)
This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on May 20,, 2025. The transaction was inadvertently reported using transaction code "A" instead of the correct code "P." The original Form 4, filed on May 20, 2025, is being amended by this Form 4 Amendment to correct an administrative error which miscalculated the amount of 21,755 beneficially owned shares after the purchase of 2,748 shares when in fact the correct number of beneficially owned shares was 25,795. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned. |
Common
|
2,748 |
| 2025-05-19 | Cornog William L |
Director |
Buy↑
Filing footnotes — Common (Direct)
This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on May 20,, 2025. The transaction was inadvertently reported using transaction code "A" instead of the correct code "P." The original Form 4, filed on May 20, 2025, is being amended by this Form 4 Amendment to correct an administrative error which miscalculated the amount of 19,007 beneficially owned shares after the purchase of 4,152 shares when in fact the correct number of beneficially owned shares was 23,047. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned. |
Common
|
4,152 |
| 2025-05-16 | Cornog William L |
Director |
Buy↑
Filing footnotes — Common (Direct)
This amendment is being filed to correct an administrative error in the transaction code reported in the original Form 4 filed on May 20,, 2025. The transaction was inadvertently reported using transaction code "A" instead of the correct code "P." The original Form 4, filed on May 20, 2025, is being amended by this Form 4 Amendment to correct an administrative error which miscalculated the amount of 14,855 beneficially owned shares after the purchase of 100 shares when in fact the correct number of beneficially owned shares was 18,895. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned. |
Common
|
100 |
| 2025-05-15 | Starr Ephraim |
SVP, Gen Counsel & Secretary |
Other↑
|
No Securities Owned
|
0 |
| 2025-05-15 | Starr Ephraim |
SVP, Gen Counsel & Secretary |
Award↑
Filing footnotes — Common (Direct)
Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. The units will vest over three years, 33% on May 15, 2026, 33% on May 15, 2027, and 33% on May 15, 2028. |
Common
|
37,779 |
| 2025-05-09 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Open market purchase. Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $27.37 to $27.70. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. |
Common
|
4,000 |
| 2025-05-09 | Marotta John |
Director, President and CEO |
Award↑
|
Common
|
1,796 |
| 2025-05-08 | Marotta John |
Director, President and CEO |
Award↑
Filing footnotes — Common (Direct)
The original Form 4, filed May 12, 2025, is being amended by this Form 4 Amendment solely to correct an administrative error. Following the 05/08/2025 acquisition of 3,637.638 shares, the Reporting Person's Amount of Securities Beneficially Owned was 104,499.615, not 102,658.135 as originally reported. Following the 05/09/2025 acquisition of 1,796.165 shares, the Amount of Securities Beneficially Owned was correctly reported as 106,295.780. |
Common
|
3,637 |
| 2025-05-08 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Open market purchase. |
Common
|
2,000 |
| 2025-02-11 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Open market purchase. |
Common
|
2,200 |
| 2025-02-07 | Doshi Dipal |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
4,040 |
| 2025-02-07 | McLaughlin Erica |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
4,040 |
| 2025-02-07 | Davis Robyn C |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
4,040 |
| 2025-02-07 | Koffey Quentin |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Annual grant of unrestricted shares under the Issuer's 2020 Equity Incentive Plan in connection with the Reporting Person's service on the Issuer's Board of Directors (the "Board"). The number of shares was determined based on an annual grant amount of $215,000 and a price per share of $52.32 based on the average daily closing price for the 20 trading-day period immediately preceding and including February 7, 2025. No amount was paid upon grant of the shares. |
Common Stock
|
4,040 |
| 2025-02-07 | Casal Frank |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
5,168 |
| 2025-02-07 | Nova Tina Susan |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
4,040 |
| 2025-02-07 | Malus Alan J |
Director |
Award↑
Filing footnotes — Common (Direct)
Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Common
|
4,040 |
| 2025-02-03 | Hughes Violetta |
CHIEF ACCOUNTING OFFICER |
Sell↓
Filing footnotes — Common (Direct)
The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on January 31, 2025 of 894 restricted stock units held by the reporting person. |
Common
|
317 |
| 2025-01-31 | Zhou Ginger |
SVP and GM, Multiomics |
Buy↑
Filing footnotes — Common (Direct)
Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act |
Common
|
417 |
| 2025-01-31 | Doshi Dipal |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-12-05 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Represents two grants of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan, one grant of 23,045 units subject to time-based vesting and will vest 33% per year for three years, beginning on December 5, 2025 and another grant of 5,768 units subject to time-based vesting and will vest 50% per year for two years, beginning on December 5, 2025. No amount was paid upon grant of the units. |
Common
|
23,045 |
| 2024-12-05 | Lin Lawrence Y. |
EVP, CFO and Treasurer |
Award↑
Filing footnotes — Common (Direct)
Represents two grants of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan, one grant of 23,045 units subject to time-based vesting and will vest 33% per year for three years, beginning on December 5, 2025 and another grant of 5,768 units subject to time-based vesting and will vest 50% per year for two years, beginning on December 5, 2025. No amount was paid upon grant of the units. |
Common
|
5,768 |
| 2024-12-04 | Wang David Dong |
SVP & GM, SMS |
Other↓
Filing footnotes — Common (Direct)
The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on December 2, 2024 of 470 restricted stock units held by the reporting person. |
Common
|
140 |
| 2024-11-19 | Zhou Ginger |
SVP and GM, Multiomics |
Sell↓
Filing footnotes — Common (Direct)
Represents the sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2024 of 1,844 restricted stock units from three grants held by the reporting person and previously reported on Form 4. Represents the weighted average price for shares sold between November 18, 2024 and November 19, 2024 at a range between $38.83 and $41.48. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. |
Common
|
491 |